What Agios Pharmaceuticals Bears Saw Before The Fall

If you had backed the bullish case for Agios Pharmaceuticals in late 2025, you were buying into a story of precision therapies, aging populations, and anticipated regulatory progress. For Agios Pharmaceuticals shareholders, the loss over the past year was 22.2%, including dividends. That outcome now forces a sharper question: If PYRUKYND expansion, rapid revenue growth and a rerating to a much higher P/E were central to the thesis, which of those assumptions proved most vulnerable, and why?

This theme extends beyond Agios Pharmaceuticals. See which of 38 healthcare AI stocks may still merit a closer look.

The Argument Agios Investors Were Really Weighing

The shares cost US$40 at the start of the period, and anyone looking at Agios Pharmaceuticals had to choose between two very different but plausible stories.

The bullish view pointed to a Fair Value of US$65, a price implied by expectations baked into the optimistic model, built on PYRUKYND expansion into thalassemia and sickle cell disease, and rapid global uptake helped by clear patient identification and payer engagement.

The bearish narrative leaned on a Fair Value of US$37.23, framed around mounting payer pressure on rare disease pricing and the risk that heavier regulatory demands would slow approvals and keep research and development spending high.

What The Evidence Did To The Agios Pharmaceuticals Argument

Agios Pharmaceuticals secured European approval for PYRUKYND in alpha and beta thalassemia and reported Q2 2026 revenue of US$44.745 million versus US$12.455 million a year earlier, which supported the optimistic thesis on indication expansion and top line. The group still reported a net loss of US$100.703 million in Q2 2026, so the profitability part of the bullish case remained unproven and the evidence cut both ways.

The hinge assumption here was that PYRUKYND expansion would quickly improve both scale and earnings quality. When assessing another rare disease stock, track whether new indications and regions show up as higher reported revenue and a narrowing loss in filings, rather than relying on projected ramps or target markets.

What You Would Be Paying For In Agios Pharmaceuticals Today

Agios Pharmaceuticals now trades at US$31.38, with this selected Narrative arguing that its Fair Value sits above the current price. The story centers on mitapivat led hematology expansion, a growing rare disease franchise and tight control of operating costs backed by an about US$1b cash balance.

To see the recent fall as potential opportunity rather than warning, a buyer today would need to believe that rare hematology launches, label extensions and disciplined spending can translate into multiple durable revenue lines over time.

"The current valuation suggests the market is discounting this bullish view that Agios Pharmaceuticals is undervalued, with the share price not fully reflecting mitapivat growth, broader regulatory momentum and the contribution of pipeline assets like cevidoplenib and AG-236."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

Another Way To Read Agios

Agios shows one path into chronic disease demand. Rare blood disorders, focused pipelines, disciplined costs.

Step sideways and aging and obesity needs appear differently. Another large drug maker leans on cardiometabolic and obesity treatments.

It sells prescription medicines for heart health, diabetes, cancer, immune conditions and brain disease. Partnerships and licenses expand that reach.

New obesity and diabetes drugs are only part of its story. Cancer, autoimmune and genetic therapies are being built as separate pillars.

If those pillars grow alongside weight loss medicines, you see another way to tap the same long term pressures shaping Agios.

It is written up in full, assumptions and all. → Explore the Narrative that puts this company 16% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com